Bristol-Myers Squibb-U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*

百时美施贵宝(US:BMY) Businesswire·2026-10-01 05:32

核心观点 - 美国FDA批准扩大BMS旗下CAMZYOS的适应症，用于治疗成人及儿科患者的症状性oHCM [1] 适应症扩展 - CAMZYOS获得美国FDA批准的扩大适应症，覆盖成人及儿科患者的症状性oHCM治疗 [1] - 该批准由BMS宣布，CAMZYOS为BMS旗下产品 [1]

Bristol-Myers Squibb-U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients* - Reportify